Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Nebokitug

Source date not recordedAnalyse record ↗

Anti-CCL24 antibody with completed Phase 2 PSC testing and later-stage development still subject to partnering.

Modality
CCL24-neutralizing monoclonal antibody
Availability (US)
Phase 2 SPRING study Completed; potential Phase 3 PSC study remains in preparation and partnering
Biomarkers
treatment-emergent adverse events; alkaline phosphatase; liver stiffness; fibrosis and inflammatory markers
Hallmark targeted
extracellular-matrix remodeling, fibrosis, chronic inflammation
Kind
investigational biologic
Clinical trials
NCT04595825 — Phase 2, Completed on July 2, 2026 update; NCT06210945 — Phase 2 systemic-sclerosis study Suspended on April 15, 2026 update